Business Wire

LEO Pharma announces more than half of patients on Kyntheum® (brodalumab) maintain consistent levels of complete skin clearance for more than two years

Del

NOT FOR DISTRIBUTION IN THE UNITED STATES

LEO Pharma today announced new Phase III data broadening the evidence base for the efficacy, safety and quality of life benefits of Kyntheum ® (brodalumab), a biologic treatment for people with moderate-to-severe plaque psoriasis. Results from a long-term extension study found Kyntheum® provided sustained high levels of skin clearance (PASII 100) over more than two years in those with moderate-to-severe disease.1 Separate pooled analyses from the AMAGINE clinical trials showed that patients receiving Kyntheum® reported significant health-related quality of life improvements versus placebo.2,3 These data were presented at the 26th European Academy of Dermatology (EADV) annual congress in Geneva, Switzerland.

Psoriasis is a serious, lifelong condition impacting emotional, psychological and physical health. Although its systemic nature often remains unrecognised, people living with psoriasis are at an increased risk of developing serious associated conditions, which further impact quality of life.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.5 For these reasons, lasting skin clearance of symptoms and plaques is an important treatment goal, especially for those with the most severe forms of the disease.5

Results from the AMAGINE-2 extension study confirmed Kyntheum® was able to deliver completely clear skin (PASI 100) in more than half of patients (56.2%, n=779) and almost clear skin (PASI 90) in more than three-quarters of patients (76.8%, n= 779) after two years (120 weeks) of treatment.1 The proportions of patients achieving high levels of skin clearance were comparable to results at year one (week 52) (with 53% and 78% of patients achieving PASI 100 and PASI 90, in year one respectively).1 At week 120, Kyntheum® continued to be well-tolerated with a comparable safety profile, as observed in the 52-week study.1 The most common adverse events were nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infection, arthralgia (joint pain), and headache.1

“These new data are encouraging as they demonstrate the potential long-term efficacy and safety of Kyntheum ® and reinforce its ability to provide psoriasis patients with high levels of lasting skin clearance. It is important that people with moderate-to-severe plaque psoriasis have treatment options that help them to not only achieve clear, healthy skin, but also the capability to relieve the substantial burden the disease places on patients’ everyday lives,” commented Professor Dr. Ulrich Mrowietz, Psoriasis Centre, University Medical Centre, Schleswig-Holstein, Germany.

The burden of psoriasis on quality of life is comparable to other chronic conditions like diabetes and heart diseases.6 Measuring improvements in health-related quality of life is important as they reflect a patient’s experience or perception of disease impact, which is not evaluated by PASI scores alone.7

New pooled analyses of the Phase III AMAGINE(-1,-2,-3) studies showed that significantly greater improvements in health-related quality of life were experienced with Kyntheum® compared with placebo, as measured by the Dermatology Life Quality Index (DLQI)II questionnaire.2,3 At week 12, 59% of Kyntheum® patients reported psoriasis had no impact on their overall quality of life compared to 6% of patients on placebo.3 This was experienced specifically with significant improvements across daily/leisure activities, as well as work/school lives.2 Furthermore, at week 12, 43% of Kyntheum® patients were no longer embarrassed or self-conscious about their psoriasis.3

“Psoriasis is not just a skin condition and the full impact of the disease is often underestimated,” said Gitte Pugholm Aabo, President and CEO, LEO Pharma. “At LEO Pharma we are dedicated to supporting patients with innovative treatment solutions such as Kyntheum ® that can help patients live a more positive life, clear of their skin condition.”

Kyntheum® was granted marketing authorisation by the European Commission in July 20178 and is the first and only biologic that selectively targets the IL-17 receptor subunit A.9,10 By binding to this specific receptor on the cells of the skin, rather than targeting free inflammatory mediators, Kyntheum® blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are involved in psoriasis plaque formation.10,11,12 This mechanism of action is different to all other psoriasis biologics currently available.10,13

A total of 16 Kyntheum® abstracts are being presented at the 2017 EADV annual congress.

- ENDS-

NOTES TO EDITORS

About Kyntheum ®

Kyntheum® (brodalumab) is the only fully human monoclonal antibody that selectively targets the IL-17 receptor subunit A.10,13 By binding to the receptor with high affinity, Kyntheum® effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis.ý13,14

The psoriasis clinical studies programme for Kyntheum® consisted of three clinical trials; AMAGINE-1 (n=661), AMAGINE-2 (n=1831) and AMAGINE-3 (n=1881).15,16 Results showed Kyntheum® 210mg offered more patients complete skin clearance (PASI 100) at 12 weeks compared to patients treated with ustekinumab [AMAGINE-2: 44% (n=272) versus 22% (n=65), p<0.001; AMAGINE-3: 37% (n=229) versus 19% (n=58), p<0.001].15

In AMAGINE-1 83% of patients on Kyntheum® 210mg achieved PASI 75 compared to 3% of patients treated with placebo at 12 weeks [83.3% (n=185) versus 2.7% (n=6), p<0.001] and 76% of patients achieved sPGAIII success versus 1% of patients treated with placebo [75.7% (n=168) versus 1.4% (n=3), p<0.001].16

In the AMAGINE trials more than half (53-56%) of patients on continuous Kyntheum® treatment achieved PASI 100 at week 52.16,17

Patients also reported experiencing improved health-related quality of life after four weeks of treatment with Kyntheum®.18 After 12 weeks of treatment, seven in 10 patients (72%, n=29/40, p<0.0001) reported psoriasis no longer impaired their health-related quality of life, (0/1 DLQI) compared with placebo (5%, n=2/37).18

Data from the three large randomised, controlled AMAGINE clinical trials, found Kyntheum® to be well tolerated, with an acceptable safety profile.19 The most common adverse events were arthralgia (joint pain), headache, fatigue, diarrhoea and oropharyngeal (mouth and throat) pain.16

In July 2016, LEO Pharma entered into a partnership agreement with AstraZeneca granting LEO Pharma exclusive licence to develop and commercialise Kyntheum® in Europe.IV Outside of Europe, Valeant Pharmaceuticals has global commercial rights for brodalumab except in Japan and certain other Asian countries, where the rights are held by Kyowa Hakko Kirin Co. Ltd.

About psoriasis

Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.5 The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).5

An estimated 125 million people worldwide live with psoriasis,20 including nearly 14 million Europeans.21

Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.22 People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,4 including heart disease23,24,25 and metabolic diseases (a combination of diabetes, high blood pressure and obesity).26 Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.27

According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.5

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. LEO Pharma offers a comprehensive range of integrated care solutions for control and relief of psoriasis. By expanding its portfolio into biologics, through the approval of Kyntheum®, the company is set to become the world’s leading dermatology company.

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

For more information, visit www.leo-pharma.com

Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal

Follow us on Twitter: www.twitter.com/leohealthyskin

Visit us at LinkedIn: www.linkedin.com/company/leo-pharma

I The Psoriasis Area and Severity Index (PASI) score is used in clinical trials to indicate a % change in disease, i.e. PASI 75 is defined as the proportion of patients that reach ≥ 75% improvement in Psoriasis Area and Severity Index score. PASI 90 or PASI 100 indicates patients who have achieved almost clear or complete skin clearance

II The Dermatology Life Quality Index (DLQI), is a tool commonly used by Dermatologists to assess the quality of life impact of skin disease across areas such as work and social activities as well as symptoms and patients’ feelings about their condition. The data presented at EADV refers to responses to specific sections of this overall DLQI questionnaire.

III sPGA success is defined as patients who achieved a static Physician’s Global Assessment 0 or 1

IV Kyntheum® is not approved by Swissmedic for marketing in Switzerland.

References

1. Lebwohl M, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1790

2. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1791

3. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1792

4. Reich K. Eur Acad Dermatol Venereol. 2012; 26(2):3-11

5. World Health Organization (WHO). Global Report on Psoriasis. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (Accessed September 2017)

6. Rapp SR, et al. J Am Acad Dermatol 1999;41:401-407

7. Grob JJ. J Invest Dermatol. 2007;127:2299-2301

8. European Medicines Agency, European public assessment report, Kyntheum® (brodalumab). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003959/human_med_002054.jsp&mid=WC0b01ac058001d124 (Accessed September 2017)

9. Kyntheum®. Summary of Product Characteristics. 2017

10. Campa M, et al. Dermatol Ther. 2016;6:1–12

11. Beringer A, et al. Trends Mol Med. 2016; 22: 230-41

12. Russell CB, et al. J Immunol. 2014; 192: 3828-36

13. Coimbra S, et al. Core Evidence. 2014;9:89-97

14. Papp K, et al. N Engl J Med 2012;336:1181-9

15. Lebwohl M, et al. N Engl J Med. 2015;373:1318-28

16. Papp K, et al. Br J Dermatol. 2016;175:273–286

17. Supplement to: Lebwohl M, et al. N Engl J Med. 2015;373:1318-28

18. Gordon KB, et al. Br J Dermatol. 2014;170:705–15

19. Attia A, et al. Clin Drug Investig. 2017; DOI: 10.1007/s40261-017-0500-9

20. The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/ (Accessed September 2017)

21. Ortonne J, et al. Eur J Dermatol. 2004;14:41–45

22. National Institute for Health and Care Excellence (NICE) Psoriasis: assessment and management guidelines. Available at: https://www.nice.org.uk/guidance/cg153/chapter/1-Guidance#systemic-therapy (Accessed September 2017)

23. Gelfand JM, et al. JAMA. 2016;296:1735-41

24. Ahlehoff O, et al. Eur Heart J. 2012;33:2054-64

25. Lowes MA, et al. Ann Rev Immunol. 2014;32:227-35

26. Langan SM, et al. J Invest Dermatol. 2012 Mar; 132(3 0 1): 556–562

27. Dalgard F, et al. JID. 2015;135(4), 984-991

Contact information

LEO Pharma
Global media contacts
Henrik Steen Heskjær Kyndlev
Head of Global External Communication
Email: HDTDK@leo-pharma.com
Mobile: +45 3140 6180
or
Marie Schleimann Nordlund
Snr Global Patient Communication Manager
Email: marie.nordlund@leo-pharma.com
Mobile: +45 3126 3734

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Rimilia Wins Expedia® Partner Solutions Account21.2.2019 11:00:00Pressemelding

Rimilia, a financial technology company, today announced that Expedia Partner Solutions (EPS), Expedia’s Business-to-Business partner network, selected Rimilia solutions to automate incoming payments. Rimilia will enable EPS to automate the application of their payments in 20 different currencies to open lodging supply/invoices from all of Expedia Group’s hotel, airline, car rental and holiday travel agency partners. Headquartered in Bellevue, Washington, Expedia Group is one of the world’s largest online travel companies with nearly $100 billion in gross bookings, $11 billion in revenue and 24,000 employees worldwide1. The Expedia Partner Solutions division supports thousands of travel partners with technology, travel supply and support services. Jeremy Hayes, Senior Manager for EAC Accounting at Expedia Partner Solutions, stated, “Our team manages cash and collection and applies payments from our travel partners all over the globe in multiple currencies. We have been looking for ways

emporia Showcases Four Products at Mobile World Congress21.2.2019 10:00:00Pressemelding

According to a 2018 emporia survey, 31 per cent of people over 65 and 50 per cent of 65 to 70-year-olds own a mobile phone with internet access. Meanwhile 85 per cent of smartphone users over the age of 65 use WhatsApp or other messenger services to stay in touch with friends and family. 59 per cent of grandchildren use WhatsApp to share their lives with grandparents. emporiaTOUCHsmart TOUCHsmart is a new clamshell smartphone from emporia. The combination of touch screen and physical keyboard is tailored to the needs of older generations. WhatsApp is pre-installed with a shortcut button, while emporia’s famous emergency system – which automatically calls up to five numbers at the touch of a button - instis a sense of security. emporiaSmart.3 The new Smart.3 smartphone has clear menu navigation in a stylish design. It features a 13 megapixel rear and 8 megapixel front camera and has a physical home button to make it simple to return to the main menu. The smartphone is splash proof and i

Toshiba Memory Corporation Develops New Bridge Chip Using PAM 4 to Boost SSD Speed and Capacity21.2.2019 09:52:00Pressemelding

Toshiba Memory Corporation, the world leader in memory solutions, today announced the development of a bridge chip that realizes high-speed and large-capacity SSDs. Using developed bridge chips with a small occupied area and low-power consumption, the company has succeeded in connecting more flash memory chips with fewer high-speed signal lines than with the conventional method of no bridge chips. This result was announced in San Francisco on February 20, at the International Solid-State Circuits Conference 2019 (ISSCC 2019). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005378/en/ Fig. 1 Connection using bridge chips (Graphic: Business Wire) In SSDs, multiple flash memory chips are connected to a controller that manages their operation. As more flash memory chips are connected to a controller interface, operating speed degrades, so there are limits to the number of chips that can be connected. In order to increase ca

GSMA: Low Power Mobile IoT Networks Now Available from All Leading IoT Operators Worldwide21.2.2019 09:00:00Pressemelding

The GSMA today announced that Mobile IoT or Low Power Wide Area (LPWA) networks are now globally available in licensed spectrum in 49 markets1 around the world following 93 launches by 50 different mobile operators across both LTE-M and NB-IoT. Coverage is now expected to reach approximately 93% of the world’s largest IoT markets by Q2 20192. According to GSMA Intelligence forecasts, by 2025 there will be 3.5 billion cellular IoT connections, including 1.9 billion licensed LPWA connections3. “The speed with which these networks have been standardized and deployed around the world is staggering. They are now available in every major IoT market encouraging the development of innovative new products and services across a wide range of sectors,” commented Alex Sinclair, Chief Technology Officer, GSMA. “The market clearly sees the benefit of solutions in licensed spectrum that offer flexibility, adaptability, security and lower cost. They are also future proofed for the 5G era and will supp

Meggitt Training Systems to Highlight Expanded Virtual and Live-Fire Solutions at IWA Outdoor Classics21.2.2019 09:00:00Pressemelding

With two European facilities to serve shooting range customers across the continent, Meggitt Training Systems will feature the latest virtual and live-fire products March 8-11, 2019, at IWA Outdoor Classics (stand #3-211) in Nuremberg, Germany. A leader for more than nine decades in the design, equipment and installation for law enforcement, defense and commercial ranges, Meggitt Training Systems has fielded more than 13,000 range systems worldwide, including over 75,000 live-fire target systems on 122 military bases. “Meggitt understands and serves Europe’s unique live-fire training requirements thanks in part to our regional facilities in Ashford and Waardenburg,” said Mark Mears, managing director for Meggitt Training Systems Ltd. “IWA Outdoor Classics attendees are welcome to see how our unrivalled expertise can facilitate the design and construction of new and upgraded shooting ranges.” Meggitt’s display of products at IWA will include: The XWT ProImage® projected target system re

New GSMA Report Highlights Global Role of Intelligent Connectivity21.2.2019 09:00:00Pressemelding

The GSMA today issued a new report, ‘Intelligent Connectivity: How the Combination of 5G, AI, Big Data and IoT Is Set to Change Everything ,’ highlighting how 5G networks, artificial intelligence (AI), smart platforms and the Internet of Things (IoT) is set to transform the lives of citizens and businesses around the world. The in-depth report draws on fresh interviews with senior representatives from Deutsche Telekom, GSMA Intelligence, KT Corp, Telefonica and Vodafone and outlines how the convergence of computing and communications will drive a step-change in productivity by delivering real-time services across multiple sectors such as entertainment, transportation and manufacturing. GSMA Intelligence estimates that there will be 1.4 billion global 5G connections by 2025 accounting for more than 15 per cent of the mobile market. “The combination of 5G, the IoT, Big Data and AI will impact almost every aspect of our daily lives from the way we consume entertainment to the way in which